On November 4 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported that management will participate in two upcoming investor conferences (Press release, Arvinas, NOV 4, 2024, View Source [SID1234647655]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Securities Healthcare Innovation Conference on Wednesday, November 13.

Noah Berkowitz, MD, Ph.D. Chief Medical Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.

Jefferies London Healthcare Conference on Tuesday, November 19.

Noah Berkowitz, MD, Ph.D. Chief Medical Officer, and Andrew Saik, Chief Financial Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.

On November 4, 2024 ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, reported that management will participate in two upcoming investor conferences (Press release, ALX Oncology, NOV 4, 2024, View Source [SID1234647654]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2024 UBS Global Healthcare Conference
Format: Fireside chat with analyst, Trung Huynh, and 1×1 meetings
Date: Tuesday, November 12
Time: 3:30 PM PST
Location: Rancho Palos Verdes, CA
Webcast link: Available here

2024 Jefferies London Healthcare Conference
Format: Fireside chat with analyst, Michael Yee, and 1×1 meetings
Date: Tuesday, November 19
Time: 9:00 AM GMT
Location: London, UK
Webcast link: Available here

The live webcasts for the UBS and Jefferies fireside chats can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.

On November 4, 2024 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, reported that it will participate in two upcoming investor conferences in November (Press release, Allogene, NOV 4, 2024, View Source [SID1234647653]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel 2024 Healthcare Conference
Monday, November 18, 2024
5:35AM PT/8:35AM ET

Jefferies London Healthcare Conference
Wednesday, November 20, 2024
10:00AM GMT/ 5:00AM ET

Any available webcasts will be posted to the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company’s website for approximately 30 days.

On November 4, 2024 Abeona Therapeutics Inc. (Nasdaq: ABEO) reported that members of its management team will participate in upcoming investor conferences in November 2024 (Press release, Abeona Therapeutics, NOV 4, 2024, View Source [SID1234647652]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Truist Securities BioPharma Symposium: Investor meetings on Thursday, November 7, 2024.
Stifel 2024 Healthcare Conference: Fireside chat on Monday, November 18, 2024 at 4:10 p.m. ET and investor meetings.

A live webcast of the fireside chat can be accessed on the Investors section of the Abeona website under "Events" at View Source, where a replay of the events will also be available for a limited time.

On November 1, 2024 AimedBio reported to have received IND clearance from the U.S. Food and Drug Administration (FDA) for AMB302.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

– AimedBio plans to initiate a Phase 1 clinical trial in both Korea and the United States, enrolling patients with solid tumors, including bladder cancer and head and neck cancer.

– First patient dosing is expected to begin in Q1 2025 in both countries.

(Press release, AimedBio, NOV 1, 2024, View Source;s_keyword=&s_where=&start=10 [SID1234656919])